SAN DIEGO, March 2, 2011 /PRNewswire/ — Accumetrics, Inc., a
privately-held developer and marketer of the VerifyNow System, the
first rapid and easy-to-use point-of-care diagnostic system for
measuring platelet reactivity to multiple antiplatelet agents,
announced today that the company has signed an agreement with
Portola Pharmaceuticals, Inc. to develop and supply the VerifyNow
System and VerifyNowTests for use in clinical trials.
The VerifyNow System is widely used by practicing physicians to
assess patients’ platelet response to various antiplatelet
therapies already available on the market, such as aspirin, P2Y12
inhibitors (e.g. Plavix® and Effient®)and GP IIb/IIIa
inhibitors. The VerifyNow System is also a frequently used tool of
clinical researchers to measure the antiplatelet effect of drugs in
development. By incorporating the VerifyNow System in
pharmaceutical clinical trials, data are generated to support the
integration of platelet reactivity testing in the patient care
pathway as new agents are introduced to the market.
“With the signing of this agreement, Accumetrics is solidifying
its role as a premier partner of pharmaceutical companies in the
development and validation of new and emerging antiplatelet drugs,”
said Timothy I. Still, President and CEO of Accumetrics.
“With the trend towards individualized and targeted
approaches to treating patients, the VerifyNow System plays an
important role at both the commercial and development ends of the
spectrum.”
The VerifyNow System is widely used in various clinical settings
where antiplatelet medications are prescribed to reduce the
occurrence of future thrombotic events such as heart attack and
stroke.
About Accumetrics Accumetrics is committed to advancing
medical understanding of platelet function and enhancing quality of
care for patients receiving antiplatelet therapies by providing
industry-leading and widely accessible diagnostic tests for
ra
‘/>”/>
